61220-36-8 Usage
Uses
Used in Smoking Cessation Aids:
Tetrahydro-1-(4-piperidinyl)-2(1H)-pyrimidinone is used as a smoking cessation aid for its ability to act as a partial nicotine receptor agonist, reducing the craving for nicotine and helping individuals quit smoking.
Used in Pharmaceutical Industry for Neurological Disorders:
In the pharmaceutical industry, tetrahydro-1-(4-piperidinyl)-2(1H)-pyrimidinone is being studied for its potential use in the treatment of neurological disorders such as Parkinson's disease, depression, and schizophrenia. Its unique chemical structure and pharmacological effects make it a promising candidate for these applications.
Overall, tetrahydro-1-(4-piperidinyl)-2(1H)-pyrimidinone has demonstrated its potential in various therapeutic applications, particularly in smoking cessation and the treatment of neurological disorders, due to its unique chemical structure and pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 61220-36-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,2,2 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 61220-36:
(7*6)+(6*1)+(5*2)+(4*2)+(3*0)+(2*3)+(1*6)=78
78 % 10 = 8
So 61220-36-8 is a valid CAS Registry Number.
61220-36-8Relevant academic research and scientific papers
Substituted heterocycles
-
, (2008/06/13)
Compounds of formula I STR1 wherein Q1, Q2, Q3, Q4 and Q5 have any of the meanings given in the specification, their N-oxides, and their pharmacuetically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
Piperidine derivatives useful as neurokinin antagonists
-
, (2008/06/13)
Compounds of formula I STR1 wherein Q1, Q2, Q3, and Q4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
